|本期目录/Table of Contents|

[1]杜书君,唐斌斌.瑞舒伐他汀治疗冠心病合并高脂血症的疗效及对血清hs-CRP的影响[J].慢性病学杂志,2019,20(12):1807-1809.
　DUShu-jun,TANGBin-bin.Effect of rosuvastatin on coronary heart disease combined with hyperlipidemia and its influence on serum high-sensitivity C-reactive protein[J].,2019,20(12):1807-1809.
点击复制

瑞舒伐他汀治疗冠心病合并高脂血症的疗效及对血清hs-CRP的影响

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:
20
期数:
2019年12期
页码:
1807-1809
栏目:
论　著
出版日期:
2019-12-28

文章信息/Info

Title:
Effect of rosuvastatin on coronary heart disease combined with hyperlipidemia and its influence on serum high-sensitivity C-reactive protein
作者:
杜书君; 唐斌斌
阳谷县人民医院药剂科，山东 阳谷 252300
Author(s):
DUShu-jun; TANGBin-bin
Pharmacy Department,YangguCountyPeople’sHospital,Yanggu252300,Shandong, China Correspondingauthor:DUShu-jun,E-mail:ziyso1@163.com
关键词:
冠心病; 高脂血症; 瑞舒伐他汀; 血清超敏C-反应蛋白
Keywords:
Coronary heart disease;  Hyperlipidemia;  Rosuvastatin;  Serum high-sensitivity C-reactive pro-tein
分类号:
R541.4
DOI:
-
摘要:
目的 分析瑞舒伐他汀对冠心病合并高脂血症患者的治疗效果及对血清超敏C-反应蛋白（hs-CRP）的 影响。方法 选取2018年1月—2019年4月阳谷县人民医院103例冠心病合并高脂血症患者作为研究对象，按 照数字分组法分为治疗组（n=52）和对照组（n=51）。对照组应用阿托伐他汀治疗，治疗组应用瑞舒伐他汀治 疗，对比两组治疗前后血脂水平、血清hs-CRP、颈动脉内中膜厚度（IMT）。结果 治疗后，两组hs-CRP水 平均降低，治疗组hs-CRP水平（2.08±0.45）mmol/L低于对照组的（5.84±1.12）mmol/L，差异有统计学意 义（P<0.05）。治疗前，两组甘油三酯（TG）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）和高密度脂蛋 白胆固醇（HDL-C）水平比较，差异无统计学意义（P>0.05）；治疗后，两组TG、TC、LDL-C和HDL-C水 平均有改善，且治疗组优于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，治疗组IMT水平（0.60± 0.22）mm，低于对照组的（0.84±0.13）mm，差异有统计学意义（P<0.05）。结论 冠心病合并高脂血症患者 应用瑞舒伐他汀可对血脂水平进行有效调节，并降低hs-CRP水平，有较高的用药价值和安全性。
Abstract:
Objective To analyze the therapeutic effect of rosuvastatin on patients with coronary heart disease combined with hyperlipidemia and its effect on serum high-sensitivity C-reactive protein（hs-CRP）. Methods From January2018 to April 2019, 103 patients with coronary heart disease com-bined with hyperlipidemia in Yanggu County People’s Hospital were selected as the research subjects and were divided into treatment group（n=52）and control group（n=51）. The control group was treated with atorvastatin, and the treatment group was treated with rosuvastatin. The blood lipid lev-els, serum hs-CRP, and carotid intima-media thickness（IMT）were compared between the two groups before and after treatment. Results After treatment, the levels of hs-CRP in the two groups were decreased. The level of hs-CRP in the treatment group was statistically lower than that in the control group [（2.08±0.45）mmol/L vs.（5.84±1.12）mmol/L,P＜0.05]. Before treatment, there was no significant difference in the levels of TG, TC, LDL-C and HDL-C between the two groups（all P>0.05）. After treatment, the levels of TG, TC, LDL-C and HDL-C in both groups were im-proved, especially in the treatment group（all P<0.05）. The difference between the two groups was statistically significant（P<0.05）. After treatment, the IMT level in the treatment group was （0.60± 0.22）mm, which was lower than that in the control group [（0.84±0.13）mm], and the differencewas statistically significant（P<0.05）. Conclusion The use of rosuvastatin in patients with coronary heart disease and hyperlipidemia can effectively regulate blood lipid levels and reduce hs-CRP levels, which has high drug value and safety.

参考文献/References:

[1] 杨琼琼,吴凡,程国平.对比分析不同剂量瑞舒伐他汀治疗老年冠 心病合并高脂血症的疗效[J].北方药学,2018,15(10):86-87. [2] 中华人民共和国卫生部.冠状动脉粥样硬化性心脏病诊断标准 [S].中华人民共和国卫生行业标准WS319-2010. [3] 毕君霞,刘丽,高燕燕.瑞舒伐他汀对冠心病合并高脂血症患者血 糖影响分析[J].中外医疗,2018,37(13):116-118. [4] 张海龙,赵宝成,刘育鹏.复方丹参滴丸联合阿托伐他汀治疗冠心 病并高脂血症的疗效及对血清TRAIL的影响[J].心血管康复医 学杂志,2019,28(3):360-364. [5] 张寒娟,汪麒.瑞舒伐他汀钙对冠心病伴有高脂血症患者的临床 疗效及其对血脂和血糖水平改善的影响[J].抗感染药学,2019(1): 182-184. [6] 房松.瑞舒伐他汀治疗冠心病合并高脂血症患者的效果探讨[J]. 中国实用医药,2019(8):74-75. [7] 刘晓宁.瑞舒伐他汀对冠心病合并高脂血症患者炎症因子与内皮 功能的影响[J].航空航天医学杂志,2019,30(7):840-841. [8] 高堃,王琦.瑞舒伐他汀治疗冠心病合并高脂血症的效果观察[J]. 中国继续医学教育,2019,11(13):137-140.

备注/Memo

备注/Memo:
作者简介：杜书君，硕士研究生，主管药师，研究方向：临床药学 通信作者：杜书君，E-mail：ziyso1@163.com
更新日期/Last Update: 2019-12-28